Armed antibody player ADC lands a $105M mega-round to back pipeline construction
Chris Martin’s ADC Therapeutics has roped in a $105 million mega-round to back his antibody-drug conjugate startup ADC Therapeutics, based in Lausanne, Switzerland. Founding investor Auven Therapeutics came back in for the second fundraising, along with the Wild Family Office and pharma giant AstraZeneca, which has been partnered with the biotech.
The biotech has now raised $255 million for its work, with plans to launch an IPO when the timing is right. And some of this new money is being reserved to build out manufacturing operations.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.